Index
1 Market Overview of Gestational Diabetes Treatment
1.1 Gestational Diabetes Treatment Market Overview
1.1.1 Gestational Diabetes Treatment Product Scope
1.1.2 Gestational Diabetes Treatment Market Status and Outlook
1.2 Global Gestational Diabetes Treatment Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Gestational Diabetes Treatment Market Size by Region (2018-2029)
1.4 Global Gestational Diabetes Treatment Historic Market Size by Region (2018-2023)
1.5 Global Gestational Diabetes Treatment Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Gestational Diabetes Treatment Market Size (2018-2029)
1.6.1 North America Gestational Diabetes Treatment Market Size (2018-2029)
1.6.2 Europe Gestational Diabetes Treatment Market Size (2018-2029)
1.6.3 Asia-Pacific Gestational Diabetes Treatment Market Size (2018-2029)
1.6.4 Latin America Gestational Diabetes Treatment Market Size (2018-2029)
1.6.5 Middle East & Africa Gestational Diabetes Treatment Market Size (2018-2029)
2 Gestational Diabetes Treatment Market by Type
2.1 Introduction
2.1.1 Insulin
2.1.2 SGLT-2 Inhibitors
2.1.3 Alpha-glucosidase Inhibitors
2.1.4 Others
2.2 Global Gestational Diabetes Treatment Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Gestational Diabetes Treatment Historic Market Size by Type (2018-2023)
2.2.2 Global Gestational Diabetes Treatment Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Gestational Diabetes Treatment Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Gestational Diabetes Treatment Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Gestational Diabetes Treatment Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Gestational Diabetes Treatment Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Gestational Diabetes Treatment Revenue Breakdown by Type (2018-2029)
3 Gestational Diabetes Treatment Market Overview by Application
3.1 Introduction
3.1.1 Hospital Pharmacies
3.1.2 Retail Pharmacies
3.1.3 Online Pharmacies
3.2 Global Gestational Diabetes Treatment Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Gestational Diabetes Treatment Historic Market Size by Application (2018-2023)
3.2.2 Global Gestational Diabetes Treatment Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Gestational Diabetes Treatment Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Gestational Diabetes Treatment Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Gestational Diabetes Treatment Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Gestational Diabetes Treatment Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Gestational Diabetes Treatment Revenue Breakdown by Application (2018-2029)
4 Gestational Diabetes Treatment Competition Analysis by Players
4.1 Global Gestational Diabetes Treatment Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Gestational Diabetes Treatment as of 2022)
4.3 Date of Key Players Enter into Gestational Diabetes Treatment Market
4.4 Global Top Players Gestational Diabetes Treatment Headquarters and Area Served
4.5 Key Players Gestational Diabetes Treatment Product Solution and Service
4.6 Competitive Status
4.6.1 Gestational Diabetes Treatment Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Biocon Limited
5.1.1 Biocon Limited Profile
5.1.2 Biocon Limited Main Business
5.1.3 Biocon Limited Gestational Diabetes Treatment Products, Services and Solutions
5.1.4 Biocon Limited Gestational Diabetes Treatment Revenue (US$ Million) & (2018-2023)
5.1.5 Biocon Limited Recent Developments
5.2 Eli Lilly
5.2.1 Eli Lilly Profile
5.2.2 Eli Lilly Main Business
5.2.3 Eli Lilly Gestational Diabetes Treatment Products, Services and Solutions
5.2.4 Eli Lilly Gestational Diabetes Treatment Revenue (US$ Million) & (2018-2023)
5.2.5 Eli Lilly Recent Developments
5.3 Novo Nordisk
5.3.1 Novo Nordisk Profile
5.3.2 Novo Nordisk Main Business
5.3.3 Novo Nordisk Gestational Diabetes Treatment Products, Services and Solutions
5.3.4 Novo Nordisk Gestational Diabetes Treatment Revenue (US$ Million) & (2018-2023)
5.3.5 Boehringer Ingelheim GmbH Recent Developments
5.4 Boehringer Ingelheim GmbH
5.4.1 Boehringer Ingelheim GmbH Profile
5.4.2 Boehringer Ingelheim GmbH Main Business
5.4.3 Boehringer Ingelheim GmbH Gestational Diabetes Treatment Products, Services and Solutions
5.4.4 Boehringer Ingelheim GmbH Gestational Diabetes Treatment Revenue (US$ Million) & (2018-2023)
5.4.5 Boehringer Ingelheim GmbH Recent Developments
5.5 Sanofi S.A.
5.5.1 Sanofi S.A. Profile
5.5.2 Sanofi S.A. Main Business
5.5.3 Sanofi S.A. Gestational Diabetes Treatment Products, Services and Solutions
5.5.4 Sanofi S.A. Gestational Diabetes Treatment Revenue (US$ Million) & (2018-2023)
5.5.5 Sanofi S.A. Recent Developments
5.6 Sun Pharmaceutical Industries Limited
5.6.1 Sun Pharmaceutical Industries Limited Profile
5.6.2 Sun Pharmaceutical Industries Limited Main Business
5.6.3 Sun Pharmaceutical Industries Limited Gestational Diabetes Treatment Products, Services and Solutions
5.6.4 Sun Pharmaceutical Industries Limited Gestational Diabetes Treatment Revenue (US$ Million) & (2018-2023)
5.6.5 Sun Pharmaceutical Industries Limited Recent Developments
5.7 Merck
5.7.1 Merck Profile
5.7.2 Merck Main Business
5.7.3 Merck Gestational Diabetes Treatment Products, Services and Solutions
5.7.4 Merck Gestational Diabetes Treatment Revenue (US$ Million) & (2018-2023)
5.7.5 Merck Recent Developments
5.8 Novartis
5.8.1 Novartis Profile
5.8.2 Novartis Main Business
5.8.3 Novartis Gestational Diabetes Treatment Products, Services and Solutions
5.8.4 Novartis Gestational Diabetes Treatment Revenue (US$ Million) & (2018-2023)
5.8.5 Novartis Recent Developments
5.9 Adocia
5.9.1 Adocia Profile
5.9.2 Adocia Main Business
5.9.3 Adocia Gestational Diabetes Treatment Products, Services and Solutions
5.9.4 Adocia Gestational Diabetes Treatment Revenue (US$ Million) & (2018-2023)
5.9.5 Adocia Recent Developments
5.10 Peptron
5.10.1 Peptron Profile
5.10.2 Peptron Main Business
5.10.3 Peptron Gestational Diabetes Treatment Products, Services and Solutions
5.10.4 Peptron Gestational Diabetes Treatment Revenue (US$ Million) & (2018-2023)
5.10.5 Peptron Recent Developments
5.11 AstraZeneca plc
5.11.1 AstraZeneca plc Profile
5.11.2 AstraZeneca plc Main Business
5.11.3 AstraZeneca plc Gestational Diabetes Treatment Products, Services and Solutions
5.11.4 AstraZeneca plc Gestational Diabetes Treatment Revenue (US$ Million) & (2018-2023)
5.11.5 AstraZeneca plc Recent Developments
5.12 Pfizer, Inc
5.12.1 Pfizer, Inc Profile
5.12.2 Pfizer, Inc Main Business
5.12.3 Pfizer, Inc Gestational Diabetes Treatment Products, Services and Solutions
5.12.4 Pfizer, Inc Gestational Diabetes Treatment Revenue (US$ Million) & (2018-2023)
5.12.5 Pfizer, Inc Recent Developments
5.13 Takeda Pharmaceutical Company Ltd
5.13.1 Takeda Pharmaceutical Company Ltd Profile
5.13.2 Takeda Pharmaceutical Company Ltd Main Business
5.13.3 Takeda Pharmaceutical Company Ltd Gestational Diabetes Treatment Products, Services and Solutions
5.13.4 Takeda Pharmaceutical Company Ltd Gestational Diabetes Treatment Revenue (US$ Million) & (2018-2023)
5.13.5 Takeda Pharmaceutical Company Ltd Recent Developments
5.14 Abbott
5.14.1 Abbott Profile
5.14.2 Abbott Main Business
5.14.3 Abbott Gestational Diabetes Treatment Products, Services and Solutions
5.14.4 Abbott Gestational Diabetes Treatment Revenue (US$ Million) & (2018-2023)
5.14.5 Abbott Recent Developments
5.15 Antares Pharma
5.15.1 Antares Pharma Profile
5.15.2 Antares Pharma Main Business
5.15.3 Antares Pharma Gestational Diabetes Treatment Products, Services and Solutions
5.15.4 Antares Pharma Gestational Diabetes Treatment Revenue (US$ Million) & (2018-2023)
5.15.5 Antares Pharma Recent Developments
5.16 INJEX Pharma AG
5.16.1 INJEX Pharma AG Profile
5.16.2 INJEX Pharma AG Main Business
5.16.3 INJEX Pharma AG Gestational Diabetes Treatment Products, Services and Solutions
5.16.4 INJEX Pharma AG Gestational Diabetes Treatment Revenue (US$ Million) & (2018-2023)
5.16.5 INJEX Pharma AG Recent Developments
5.17 Daiichi Sankyo
5.17.1 Daiichi Sankyo Profile
5.17.2 Daiichi Sankyo Main Business
5.17.3 Daiichi Sankyo Gestational Diabetes Treatment Products, Services and Solutions
5.17.4 Daiichi Sankyo Gestational Diabetes Treatment Revenue (US$ Million) & (2018-2023)
5.17.5 Daiichi Sankyo Recent Developments
6 North America
6.1 North America Gestational Diabetes Treatment Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Gestational Diabetes Treatment Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Gestational Diabetes Treatment Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Gestational Diabetes Treatment Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Gestational Diabetes Treatment Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Gestational Diabetes Treatment Market Dynamics
11.1 Gestational Diabetes Treatment Industry Trends
11.2 Gestational Diabetes Treatment Market Drivers
11.3 Gestational Diabetes Treatment Market Challenges
11.4 Gestational Diabetes Treatment Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List